Researchers Identified New Molecule for ALS Therapy
A new small molecule could help address neurological damage in ALS and FTD patients.
Updated on Oct. 3, 2026 in Alzheimer’s
Researchers have identified a small molecule, SCC944, that modulates a key protein complex linked to amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). This finding could offer a new therapeutic path for managing neurodegenerative conditions.
Why it matters
Dysregulation of the ARF1 protein complex is implicated in the progression of these diseases, and identifying ways to correct this process is a critical step in drug discovery. This discovery provides a potential mechanism for future treatments that address the underlying biology of ALS and FTD.
Researchers identified elevated tyrosine-phosphorylated ASAP1 at amino acid position 782 in the human motor cortex of sporadic and C9orf72-mutated ALS patients. The small molecule SCC944 (MCULE identifier 5,095,997,944) was shown to bind ARF1 and reduce its GTP-bound levels.
The players
SCC944
A small molecule identified through computer-aided drug design as a potential modulator of the ARF1-CSW protein complex.
C9orf72
A gene whose hexanucleotide repeat expansion is a known genetic cause of ALS and frontotemporal dementia.
The details
The C9orf72 gene, when mutated with hexanucleotide repeat expansions, is a known driver of ALS and FTD. Scientists found that the CSW protein complex, normally responsible for regulating ARF1, is impaired, leading to cellular disorganization. By using computer-aided design and in-silico screening, they identified SCC944 as a modulator that binds ARF1. This molecule helps restore proper cellular structure by influencing the organization of Golgi bodies, microtubules, and mitochondria.
Timeline
October 3, 2026: Findings were published.
Health Landscape
This research expands the targetable pathways within the C9orf72-mediated ALS research pipeline. It marks a shift toward rational, in-silico drug design to address the complex protein dysregulation found in motor neuron diseases.
This discovery is in the early stages of development and does not yet affect current treatment plans. Patients and families concerned about ALS or FTD should continue to consult their neurologists regarding established standard-of-care options.
The takeaway
The identification of SCC944 highlights how computer-aided drug design is advancing the search for treatments targeting the underlying molecular causes of neurodegenerative disease. Tracking updates on clinical development programs for ALS and FTD remains the most important step for patients following these trends.
Further reading
Learn more about the latest research into neurodegenerative pathways in Alzheimer’s.
Source note: This article includes information reported by Nature.
